← Back to list
Sirolimus Protein-Bound Particles for Injectable Suspension Albumin-Bound (Fyarro) (CPB 1001, reviewed 2026-03-25)
Effective date
Mar 16, 2022
Identified
Aug 16, 2026
Summary
Aetna has issued a new medical policy (CPB 1001, effective March 16, 2022, reviewed March 25, 2026) establishing coverage criteria for Fyarro (sirolimus protein-bound particles albumin-bound) for treatment of locally advanced unresectable/metastatic malignant PEComa and advanced/recurrent/metastatic uterine sarcoma. Precertification is required for all covered indications. Billing teams must implement prior authorization workflows and update systems to recognize covered diagnoses and the specific HCPCS code J9331.
Get alerts when payers change rules like this one
We check Aetna and other payers every day and email you when a change matches your specialty and state.
Get Aetna alertsPolicy Monitoring is free. No card required.
What to do
Action · 11 steps
01REQUIREMENTS:
- Immediately: Billing and precertification teams must establish prior authorization (precertification) workflow for Fyarro.
02Update billing system to flag claims with HCPCS code J9331 for mandatory precertification.
03- Before next claim submission: Configure system to require precertification routing to Aetna at phone (866) 752-7021 or fax (888) 267-3277 for all Fyarro claims.
04All Aetna participating providers and members in applicable plan designs require precertification.
05- Immediately: Train providers and billing staff that Fyarro is covered ONLY when prescribed for:
1) Locally advanced unresectable or metastatic malignant PEComa (ICD-10: C48.0-C48.2, C48.8, C49.4-C49.5, C49.8-C49.9)
2) Advanced, recurrent, metastatic, or inoperable uterine sarcoma (PEComa) (ICD-10: C55)
- Before claim submission: Require providers to submit Statement of Medical Necessity (SMN) precertification forms (available through Specialty Pharmacy Precertification portal) documenting that member meets one of two covered indications above and drug is used as single agent.
06- Update billing software: Reject or hold any Fyarro claims (J9331) billed for other indications (will be classified as experimental/investigational/unproven).
07Route all off-label indication requests to precertification team for denial processing.
08- For continuation of therapy: Precertification team must reauthorize Fyarro only when prior authorization shows no evidence of unacceptable toxicity or disease progression.
09Block reauthorization if either condition present.
10- Billing team responsible: Failure to obtain precertification will result in claim denials.
11Ensure all claims include precertification authorization number from Aetna before processing.
Codes mentioned
9636096361963659636696367963689641396414964159641696417J9331C48.0C48.1C48.2C48.8C49.4C49.5C49.8C49.9C55D49.2Z85.831
Original notice
Sirolimus Protein-Bound Particles for Injectable Suspension Albumin-Bound (Fyarro) (CPB 1001, reviewed 2026-03-25)
aetna.com · Always check the source before changing claims.
Related changes
See all Aetna changes →Mirvetuximab Soravtansine-gynx (Elahere) (CPB 1021, reviewed 2026-01-27)MediumEffective Feb 6, 2023 · Medical PolicyPemetrexed Products (CPB 0687, reviewed 2026-07-17)MediumNo effective date · Medical PolicyDenileukin Diftitox-cxdl (Lymphir) (CPB 1070, reviewed 2026-04-09)MediumEffective Nov 13, 2024 · Medical PolicyPaclitaxel, Albumin-Bound (CPB 0834, reviewed 2026-05-28)MediumNo effective date · Medical PolicyBrowse every Aetna change in the policy list